MannKind Corp (NAS:MNKD)
$ 6.61 -0.06 (-0.9%) Market Cap: 1.84 Bil Enterprise Value: 1.83 Bil PE Ratio: 83.38 PB Ratio: 0 GF Score: 74/100

MannKind Corp at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2023 / 12:10PM GMT
Release Date Price: $4.3 (-1.38%)
Unidentified Analyst

Good morning. I'm Sam Jones from the Morgan Stanley team. I'm excited to have joining us today, Mike Castagna, CEO of MannKind. Before we get started, I'll read a disclaimer -- so this is research disclosure. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

So Mike, thanks very much for being here today. To start off, it would be great if you could provide an introduction to MannKind, maybe a quick overview of the great progress that you've made over the last few years and where you stand as a company today.

Michael E. Castagna
MannKind Corporation - CEO & Director

Yes, thank you. Thanks for having us today. MannKind has been around 32 years this year. It's been a long time coming. It was originally an inhaled insulin company platform that really was repurposed back in 2017

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot